- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03926052
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
February 13, 2024 updated by: Yale University
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity
This study will test the effectiveness of lisdexamfetamine (LDX) medication as a maintenance therapy for the treatment of binge-eating disorder (BED) in patients with obesity.
This is a controlled test of whether, amongst responders to acute treatments, LDX medication results in superior maintenance and longer-term outcomes compared with placebo.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Obesity is a heterogeneous problem and research has highlighted the particular significance of a subgroup with binge-eating disorder (BED), the most prevalent formal eating disorder.
Improved treatments for patients with obesity and BED are needed that can produce sustained clinical outcomes and promote weight loss.
This study (maintenance stage) RCT will provide findings from a controlled test, amongst responders to acute treatments, whether LDX medication results in superior maintenance and longer-term outcomes than placebo.
This is one of the few RCTs for BED of medication with follow-up after medication discontinuation.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Department of Psychiatry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 to 64 years old
- Meets DSM-5 criteria for binge-eating disorder
- BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and <50
- Medically cleared as determined by EKG and medical record review
- Available for the duration of the treatment and follow-up (18 months)
- Read, comprehend, and write English at a sufficient level to complete study-related materials
- Able to travel to study location (New Haven, CT) for weekly visits
Exclusion Criteria:
- Previous history of problems with LDX or other stimulants
- Current psychostimulant use or use of any medication for ADHD
- Current use of study medications: LDX (Vyvanse), Bupropion (Wellbutrin, Zyban), Naltrexone, or Contrave
- History of congenital heart disease, known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, cerebrovascular pathology including stroke, exertional chest pain, uncontrolled high blood pressure, and other serious heart problems.
- History of severe renal, hepatic, neurological, or chronic pulmonary disease or other serious, unstable medical disorder.
- Current uncontrolled hypertension
- Current uncontrolled type I or II diabetes mellitus
- Current uncontrolled thyroid illness
- Gallbladder disease
- Co-occurring severe mental illness requiring hospitalization or intensive treatment
- Endorses current active suicidal or homicidal ideation with intent or plan
- History or current alcohol or substance use disorder (smoking is not exclusionary)
- Predisposition to seizures
- History of anorexia nervosa or bulimia nervosa, or currently regularly self-inducing vomiting
- Currently taking MAOI, SSRI or strong inhibitors of CYP2D6
- History of allergy or sensitivity to the study medication or stimulant medications
- Current use of medications contraindicated with the study medications
- Currently breast feeding or pregnant, or not willing to use reliable form of contraception
- Currently taking opioid pain medications or drugs
- Currently using effective treatment (evidence-based therapeutic or psychopharmacologic) for eating and/or weight loss
- Currently participating in another clinical study in which the participant is or will be exposed to an investigational or a non-investigational drug or device
- Medical status judged by study physician as contraindication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
|
Active Comparator: LDX
|
Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binge-Eating Relapse
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Binge-Eating Relapse
Time Frame: From post-treatment to the 6-month follow-up
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
From post-treatment to the 6-month follow-up
|
Binge-Eating Relapse
Time Frame: From post-treatment to the 12-month follow-up
|
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of binge-eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 binge-eating episodes per month.
|
From post-treatment to the 12-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binge-Eating Frequency
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Binge-Eating Frequency
Time Frame: From post-treatment to the 6-month follow-up
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From post-treatment to the 6-month follow-up
|
Binge-Eating Frequency
Time Frame: From post-treatment to the 12-month follow-up
|
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using the Eating Disorder Examination interview; Binge-eating frequency will be based on the past 28 days and defined as binge-eating episodes per month.
|
From post-treatment to the 12-month follow-up
|
Eating-Disorder Psychopathology (Continuous)
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Eating-Disorder Psychopathology (Continuous)
Time Frame: From post-treatment to the 6-month follow-up
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From post-treatment to the 6-month follow-up
|
Eating-Disorder Psychopathology (Continuous)
Time Frame: From post-treatment to the 12-month follow-up
|
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
|
From post-treatment to the 12-month follow-up
|
Depressive Symptoms
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Depressive Symptoms
Time Frame: From post-treatment to the 6-month follow-up
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From post-treatment to the 6-month follow-up
|
Depressive Symptoms
Time Frame: From post-treatment to the 12-month follow-up
|
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition.
Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
|
From post-treatment to the 12-month follow-up
|
Body Mass Index (BMI)
Time Frame: From baseline interview at study enrollment to 3 months after the 12-week treatment
|
BMI is calculated using measured height and weight (e.g., percent loss)
|
From baseline interview at study enrollment to 3 months after the 12-week treatment
|
Body Mass Index (BMI)
Time Frame: From post-treatment to the 6-month follow-up
|
BMI is calculated using measured height and weight (e.g., percent loss)
|
From post-treatment to the 6-month follow-up
|
Body Mass Index (BMI)
Time Frame: From post-treatment to the 12-month follow-up
|
BMI is calculated using measured height and weight (e.g., percent loss)
|
From post-treatment to the 12-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carlos M Grilo, Ph.D., Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2019
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
April 18, 2019
First Submitted That Met QC Criteria
April 18, 2019
First Posted (Actual)
April 24, 2019
Study Record Updates
Last Update Posted (Estimated)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 13, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Signs and Symptoms, Digestive
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Hyperphagia
- Obesity
- Bulimia
- Feeding and Eating Disorders
- Binge-Eating Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Lisdexamfetamine Dimesylate
Other Study ID Numbers
- 2000022480
- 1R01DK114075-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Lisdexamfetamine Dimesylate
-
ShireCompletedMajor Depressive DisorderUnited States, Chile, Australia, Argentina, United Kingdom
-
ShireCompletedSchizophrenia and Predominant Negative SymptomsUnited States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
Gregory FabianoCompletedEfficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHDAttention Deficit Disorder With HyperactivityUnited States
-
ShireCompletedAttention-Deficit/Hyperactivity DisorderUnited States
-
ShireCompletedAttention Deficit Hyperactivity Disorder (ADHD)Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom
-
ShireCompletedBinge Eating DisorderUnited States
-
ShireCompletedBinge Eating DisorderSpain, United States, Germany
-
Aaron KeshenNova Scotia Health AuthorityTerminated
-
Clinical Study Centers, LLCShireCompletedSleep | Attention Deficit Hyperactivity DisorderUnited States